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Protein Arginine (R) methylation is the most common post-translational methylation in mammalian 
cells. Protein Arginine Methyltransferases (PRMT) 1 and 5 dimethylate their substrates on R residues, 
asymmetrically and symmetrically, respectively. They are ubiquitously expressed and play fundamental 
roles in tumour malignancies, including glioblastoma multiforme (GBM) which presents largely 
deregulated Myc activity. Previously, we demonstrated that PRMT5 associates with Myc in GBM cells, 
modulating, at least in part, its transcriptional properties. Here we show that Myc/PRMT5 protein 
complex includes PRMT1, in both HEK293T and glioblastoma stem cells (GSCs). We demonstrate that 
Myc is both asymmetrically and symmetrically dimethylated by PRMT1 and PRMT5, respectively, 
and that these modifications differentially regulate its stability. Moreover, we show that the ratio 
between symmetrically and asymmetrically dimethylated Myc changes in GSCs grown in stem versus 
differentiating conditions. Finally, both PRMT1 and PRMT5 activity modulate Myc binding at its specific 
target promoters. To our knowledge, this is the first work reporting R asymmetrical and symmetrical 
dimethylation as novel Myc post-translational modifications, with different functional properties. 
This opens a completely unexplored field of investigation in Myc biology and suggests symmetrically 
dimethylated Myc species as novel diagnostic and prognostic markers and druggable therapeutic 
targets for GBM.
The Myc (c-myc) oncogene is a transcription factor required for pivotal cell functions1. It regulates cell prolifer-
ation, metabolism, stemness maintenance1 and binds to 10% of genomic loci, usually amplifying transcription 
from already active genes2,3. Myc expression and function are deregulated in a wide variety of cancers, including 
glioblastoma multiforme (GBM)4,5. Despite more than a decade of advances in surgery and chemo-/radiotherapy, 
GBM treatment options are disconcertingly very poor and patients life expectancy is very limited (14.6 to 18 
months from diagnosis)6. GBM poor prognosis and deadly outcome seem to rely on the presence of tumour initi-
ating cells, which share many molecular and biological features with embryonic and adult stem cells and thus are 
called glioblastoma stem cells (GSCs). They are difficult to eradicate by surgery and are resistant to conventional 
radio- and chemotherapy, allowing tumour to recur overtime7. They also present the so-called “Myc signature”8, 
emphasizing the essential role Myc plays in maintaining GSC properties.
Myc is regulated by a series of post-translational modifications: phosphorylation9, acetylation10, sumoyla-
tion11, ubiquitination and consequent degradation by the proteasome machinery12. These modifications have a 
precise role in modulating Myc activity and have been suggested as potential therapeutic targets9,10.
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Figure 1. Myc/PRMT5/ PRMT1 complex. (a) Western blot. HEK293T cells were transfected with an empty or a 
FlagMyc expression vector. After 48 hrs, proteins were resolved onto a 12% polyacrylamide gel. β-actin was used 
as loading control. Uncropped images are shown in Supplementary Fig. S1a. (b) Western blot. Both HEK293T 
cells and GSCs were infected with a doxycycline inducible lentivirus carrying a shRNA against Myc (shMyc). 
After 48 hrs from doxycycline treatment, cells were lysed and proteins resolved onto a 12% polyacrilamide gel. 
Uncropped images are shown in Supplementary Fig. S1b. (c,d) Immunoprecipitations. FlagMyc/HEK293T 
cells and GSCs underwent reciprocal immunoprecipitation by using anti-Flag, anti-Myc, anti-PRMT1 and anti-
PRMT5 antibodies (and control IgGs). Uncropped images are shown in Supplementary Fig. S1c,d. (e) Western 
blot. HEK293T cells were transfected with a scrambled siRNA or a pool of siRNAs against PRMT5 or PRMT1. 
Uncropped images are shown in Supplementary Fig. S1e. (f) Immunoprecipitation. HEK293T cells were 
transfected with a scrambled siRNA or a siRNAs pool against PRMT5. The day after, cells were transfected again 
with the FlagMyc expression vector. After further 48 hrs cells were immunoprecipitated with anti-PRMT5, anti-
PRMT1 or anti-Flag antibodies (or control IgGs). Input is shown in the middle panel. The cartoon on the right 
panel outlines immunoprecipitation results. Uncropped images are shown in Supplementary Fig. S1f.  
(g) Immunoprecipitation experiments as in (f) in cells partially depleted of PRMT1 (see input, middle panel). 
The right panel outlines immunoprecipitation results. Uncropped images are shown in Supplementary Fig. S1g.
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Methylation of arginine (R) residues is the most common methylation event in mammalian cells, which mod-
ifies protein interacting properties, ruling a large amount of signaling pathways13. Three distinct types of meth-
ylated Rs occur in mammalians. Asymmetrically dimethylated arginine (ADMA) is the most frequent, followed 
by symmetrically dimethylated (SDMA) and monomethylated arginine (MMA). The enzymes responsible for R 
methylation are the Protein Arginine Methyltransferases (PRMTs). Six proteins have been reported to undoubt-
edly possess the R methyltransferase catalytic domain (PRMT1, 3, 4, 5, 6 and 8). PRMT2, 7 and 9 have sequence 
similarities with the other PRMTs and are supposed to possess an equivalent enzymatic activity13. Depending on 
the position of the methyl groups on R terminal guanidino nitrogens, PRMTs are, basically, classified into two 
types: type I PRMTs (PRMT1, 3, 4, 6 and 8) are responsible for MMA or ADMA whereas the type II PRMT5 
catalyzes MMA and SDMA13. PRMT1 is the major methyltransferase in mammalian cells. It has a wide variety of 
substrate specificity, from histone to non-histone proteins14. From a transcriptional point of view, it is known as 
an activator, since the occurrence of asymmetrically (AS) dimethylated R3 on histone H4 residues (H4R3me2as) 
is associated with transcriptionally active chromatin15. PRMT1 is deregulated in a wide variety of cancer types, 
e.g. pancreatic adenocarcinoma16, gastric17 and lung cancer18. It controls the epithelial-mesenchymal transition 
(EMT) in cancer cells19, while playing a major role in muscle20 and B cell differentiation21. PRMT5 has received 
a greater attention and has been suggested as a putative druggable target in a wide variety of tumours, including 
GBM22. Like PRMT1, it has multiple nuclear and cytoplasmic targets and catalyzes the symmetrical (S) dimeth-
ylation of H4R3 and H3R8, usually repressing transcription23, and of H3R2, activating transcription24. PRMT5 
is involved in a variety of cellular processes, such as neurogenesis25, myogenesis26, somatic cell reprogram-
ming27 and GSCs self-renewal28. Interestingly, PRMT1 and PRMT5 have been shown to interact in GBM cells, 
being PRMT1 the major responsible for the activation of cancer-related genes29. They also catalyze the S- and 
AS-dimethylation of NMyc30,31 and, very recently, it has been shown that PRMT1 is required for p300 recruitment 
to Myc-regulated gene promoters32.
We previously demonstrated that PRMT5 interacts with Myc in glioblastoma cells, including GSCs, and that 
PRMT5 participates, at least in part, in the activation of Myc target genes33. Here we show that PRMT1 associates 
with Myc/PRMT5 in both HEK293T cells and GSCs and that Myc is both S- and AS-dimethylated by PRMT5 
and PRMT1, respectively, both in vitro and in living cells. At the functional level, S-dimethylation protects Myc 
from degradation, while AS-dimethylation ensure Myc proper turnover. Finally, the inhibition of either PRMT1 
or PRMT5 activity affects Myc recruitment at promoters and has a profound effect on GSCs biological functions, 
such as neurospheres formation and differentiation capacity. These findings represent the first demonstration in 
GSCs of the presence of differentially dimethylated Myc species, with distinct properties, opening a completely 
new field of investigation in Myc-dependent GBM biology. Further, they support the hypothesis that acting on 
S-Myc post-translational modification may represent a possible route to control its function.
Results
Myc interacts with PRMT1 and PRMT5. We have previously shown that Myc induces S-dimethylation of 
R3 on histone H4 (H4R3me2s, Fig. 1a, left and ref.33) and associates with PRMT5 in both HEK293T and glioblas-
toma cells33. Since PRMT5 and PRMT1 were found associated in GBM cells29, we sought to determine whether 
Myc was able to promote also AS-dimethylation of R3 on histone H4 (H4R3me2as). To this aim, HEK293T cells 
were transfected with either a Flag-tagged Myc construct (FlagMyc/HEK293T) or an empty vector and the level 
of H4R3me2as was detected by western blot. Figure 1a, right, shows H4R3me2as induction in the presence of 
FlagMyc construct. We reasoned that these histone modifications should decrease by Myc interference. However, 
in both HEK293T and mesenchymal GSCs33,34 transduced with a lentiviral, doxycycline inducible shRNA against 
Myc (shMyc), the level of H4R3me2s were reduced, while H4R3me2as increased (Fig. 1b), suggesting that impair-
ing Myc-dependent PRMT5 activity is still sufficient to make H4R3 available for PRMT1 activity. Based on these 
data, we asked whether PRMT1, PRMT5 and Myc may interact. A series of reciprocal immunoprecipitation 
experiments, performed in FlagMyc/HEK293T cells, showed that FlagMyc associates with both PRMT5 and 
PRMT1 (Fig. 1c). No interactions were observed by transfecting the CBS-Flag vector alone, as expected (not 
shown). Consistently, the same result was obtained, at the endogenous level in GSCs (Fig. 1d). Overall, these data 
validate PRMT5/Myc interaction33 and indicate PRMT1 as a novel partner in this protein complex.
PRMT5 is required for the formation of Myc/PRMT5/PRMT1 protein complex. We next won-
dered which protein member was necessary for complex assembly. Therefore, PRMT5 and PRMT1 expression 
was blunted by specific siRNAs in HEK293T cells (Fig. 1e). In siPRMT5/HEK293T cells, PRMT5 depletion 
was associated with a decrease in H4R3me2s levels, as expected, and with an increase in H4R3me2as, under-
lying the competition between PRMT5 and PRMT1 for the same histone substrate. Intriguingly, Myc protein 
also decreased. No effect on PRMT1 expression was observed. In siPRMT1/HEK293T cells, PRMT1 decreased 
together with H4R3me2as levels, as expected, while H4R3me2s increased. Myc protein slightly increased, while 
no effect on PRMT5 expression was detected. Although PRMT5 depletion was incomplete, Fig. 1f shows that 
the anti-Flag antibody did not co-immunoprecipitate PRMT1; accordingly, the anti-PRMT1 antibody did not 
co-immunoprecipitate the FlagMyc protein, as outlined in the model shown in the right panel. In cells partially 
depleted of PRMT1 (Fig. 1g) we were still able to observe a residual amount of PRMT5/PRMT1/FlagMyc com-
plex, when an anti-PRMT1 antibody was used for immunoprecipitation. However, in anti-Flag and anti-PRMT5 
immunoprecipitates, PRMT1 was undetectable, whereas PRMT5 and FlagMyc still interacted (see the scheme 
in the right panel). Overall, these data suggest that Myc/PRMT1 binding is mediated by PRMT5 in FlagMyc/
HEK293T cells.
Myc is both symmetrically and asymmetrically dimethylated. We wondered whether Myc was 
dimethylated by both PRMT5 and PRMT1. To ask this question, in vitro methylation assays were performed 
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Figure 2. Symmetrical and asymmetrical Myc dimethylation. (a) Top, left. Western blot showing the efficacy 
of a siPRMT5 in inhibiting the expression of PRMT5-6myc (PRMT5-myc in the figure). Top, right. In vitro 
methylation assay showing S-dimethylation of a recombinant Myc protein in the presence of an overexpressed 
PRMT5. Bottom, left. Western blot showing the efficacy of a siPRMT1 in inhibiting the expression of PRMT1-
myc-Dkk (PRMT1-myc in the figure). Bottom, right. In vitro methylation assay showing AS-dimethylation 
of a recombinant Myc protein in the presence of an overexpressed PRMT1. Uncropped images are shown in 
Supplementary Fig. S2a. (b) Left. Western blot analysis showing PRMT1 and PRMT5 expression levels upon 
FlagMyc transfection in HEK293T cells. Middle. FlagMyc/HEK293T cells underwent immunoprecipitation 
with control IgG or ASYM24, SYM10 and anti-Flag antibodies. Western blot were performed by using anti-
Flag antibody for ASYM24 and SYM10 immunoprecipitations and ASYM24 or SYM10 antibodies for anti-Flag 
immunoprecipitation. Right. Western blot showing the input of the immunoprecipitations. Uncropped images 
are shown in Supplementary Fig. S2b. (c) Left. FlagMyc/HEK293T cells were treated for 24 hrs with EPZ015666 
or 9i. After additional 24 hrs, immunoprecipitations were performed by using either SYM10 or ASYM24 
antibody. Uncropped images are shown in Supplementary Fig. S2c. (d) The model depicts the competition 
between PRMT1 and PRMT5 for Myc. Inhibiting PRMT5 activity with EPZ015666 restrained FlagMyc 
S-dimethylation, while enhancing AS-dimethylation (left). The opposite was obtained by inhibiting PRMT1 
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in HEK293T cells, overexpressing either myc-tagged PRMT5 or PRMT1, in the presence or absence of specific 
siRNAs (Fig. 2a). S- or AS-dimethylation of a recombinant human Myc protein was detected by immunoprecipi-
tation experiments using antibodies recognizing either S- (SYM10 antibody) or AS- (ASYM24 antibody) dimeth-
ylated R residues. The recombinant human Myc was S-dimethylated in the presence of overexpressed PRMT5. 
S-dimethylation was restrained in the presence of a pool of PRMT5-specific siRNAs, as expected (Fig. 2a, top). 
Recombinant Myc AS-dimethylation was detected in the presence of a PRMT1-myc-Dkk overexpressed plasmid. 
No signal was observed in the presence of a specific siPRMT1 pool (Fig. 2a, bottom).
Moreover, protein extracts from HEK293T/FlagMyc cells were reciprocally immunoprecipitated by using 
SYM10 or ASYM24 or anti Flag antibodies. Western blots were performed with anti-Flag or SYM10 and ASYM24 
antibodies. Figure 2b, middle panel, shows the presence of both S and AS- dimethylated FlagMyc in HEK293T 
cells. HEK293T cells transfected with pCBSFlag vector alone represented the negative control (not shown). 
To confirm that S- and AS-Myc dimethylation were PRMT5 and PRMT1-dependent, respectively, HEK293T/
FlagMyc cells were treated for 24 hours with either 5 μM EPZ015666 – a commercially available PRMT5 specific 
inhibitor – or 3 μM 1,5‐bis(3,5‐Br2‐4‐hydroxyphenyl)‐1,4‐pentadien‐3‐one, hereafter named inhibitor 9 (9i), 
which specifically inhibits PRMT1 at this concentration35. Thereafter, immunoprecipitation experiments were 
performed with SYM10 and ASYM24 antibodies. Figure 2c, left, shows that PRMT5 inhibition impairs FlagMyc 
S-dimethylation, as expected. Conversely, PRMT5 inhibition increases the level of AS-dimethylated FlagMyc. 
These results were mirrored by similar experiments performed on cells treated with 9i. Indeed, PRMT1 inhibition 
reduced the level of AS-FlagMyc, while enhancing S-FlagMyc (Fig. 2c, left and scheme in d). In siPRMT5 trans-
fected HEK293T/FlagMyc cells, S-FlagMyc was found at low levels, as expected. Interestingly, also AS-FlagMyc 
decreased (Fig. 2e). This is not surprising, as FlagMyc/PRMT1 interaction requires the presence of PRMT5 in 
HEK293T cells (Fig. 1f). In siPRMT1 transfected HEK293T/FlagMyc cells (Fig. 2e) we detected higher levels 
of S-FlagMyc, whereas AS-FlagMyc was severely impaired, confirming the binding of PRMT5 and Myc in the 
absence of PRMT1, as previously shown in Fig. 1g.
PRMT1 and PRMT5 modulate Myc stability. It has been shown that both PRMT1 and PRMT5 sta-
bilize NMyc protein30,31. We observed that upon PRMT5 interference Myc expression decreased, while in 
PRMT1-depleted cells, Myc levels slightly increased (Fig. 1e). The same results were obtained inhibiting 
PRMT5 or PRMT1 activity, respectively (Fig. 2c, right). Therefore, two sets of experiments were performed, 
in order to investigate whether Myc stability was affected by either PRMT5 or PRMT1 catalytic inhibition in 
HEK293T/FlagMyc cells and in GSCs. To this aim, cells were treated with 5 μM EPZ015666 and 3 μM 9i for 24 
hrs. Thereafter, cycloheximide (CHX, Fig. 3a,c) or the proteasome inhibitor MG132 (Fig. 3b,d) were added to 
the culture medium, along a time course between 0 and 100 minutes (CHX) or 0 and 360 minutes (MG132). In 
HEK293T/FlagMyc cells, we found that PRMT5 inhibition produced a decrease in FlagMyc protein levels upon 
CHX administration (Fig. 3a, middle), when compared to the control vehicle. This effect was also confirmed, and 
more evident, on endogenous Myc in GSCs (Fig. 3c, middle). Importantly, the enhanced degradation of Myc pro-
tein in the presence of EPZ015666 was not responsible for the decrease in Myc S-dimethylation (Fig. 2c). Indeed, 
immunoprecipitation experiments revealed that MG132 treatment did not recover S-Myc protein levels but only 
total FlagMyc (Supplementary Fig. S6), indicating that the decrease in Myc S-dimethylation was due to PRMT5 
catalytic inhibition, although a combined effect with proteasome degradation may also be hypothesized. On the 
contrary, PRMT1 inhibition stabilized both FlagMyc and endogenous Myc upon CHX treatment (Fig. 3a,c, right). 
Proteasome inhibition by MG132 produced a similar, slight, but statistically significant, increase of FlagMyc 
protein levels in EPZ015666 and 9i HEK293T/FlagMyc treated cells (Fig. 3b). In GSCs, control vehicle and 
EPZ015666 produced similar effects upon MG132 exposure (Fig. 3d, left and middle, respectively). Conversely, 
9i dramatically enhanced endogenous GSCs Myc protein content upon MG132 administration (Fig. 3d, right). 
These experiments suggest that in both HEK293T cells and GSCs, PRMT5 have a protective effect on Myc pro-
tein, while PRMT1 may allow its proper turnover or promote its degradation. However, these effects are particu-
larly evident in GSCs.
Myc is preferentially S-dimethylated in GSCs grown as neurospheres. To evaluate endogenous 
Myc dimethylation in GSCs, neurospheres were treated for 24 hrs with either 5 μM EPZ015666 or 3 μM 9i. Cell 
extracts were immunoprecipitated with either SYM10 or ASYM24 antibody. An anti-Myc antibody was used 
to detect endogenous Myc. As shown in Fig. 4a, EPZ01566 treatment inhibited and 9i enhanced S-Myc, which 
represented the major Myc dimethylated species in GSCs. Consistently, 9i treatment decreased and EPZ015666 
increased AS-Myc levels, which were, conversely, barely detectable in vehicle-treated GSCs. The presence of 
almost exclusively S-Myc species in GSCs grown as neurospheres prompted us to investigated whether Myc 
dimethylation pattern could change exposing GSCs to different stimuli. Indeed, we found that in GSCs grown in 
2% FBS-containing medium, which promotes their astrocytic differentiation36, S-Myc levels were progressively 
reduced along a time course between 4 hours and 7 days, while AS-Myc remained quite stable (Fig. 4b, left). 
Consistently, almost total disappearance of PRMT5 and a scarce effect on PRMT1 expression upon FBS culture 
were observed, together with a reduction in Myc levels (Fig. 4b, middle). This also paralleled with immunoprecip-
itation experiments showing that Myc and PRMT1 could still interact in differentiating GSCs, while PRMT5 was 
(right). (e) HEK293T cells were transfected with a pool of specific siRNAs against either PRMT5 or PRMT1. 
The day after, cells were transfected with pCBS-FlagMyc. 48 hrs later, cells underwent immunoprecipitation 
with SYM10 or ASYM24 antibodies. Uncropped images are shown in Supplementary Fig. S2d. Abbreviations: 
SYM = SYM10; ASYM = ASYM24.
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only barely detected (Fig. 4b, right and model in panel c). In summary, these data suggest that also in GSCs Myc is 
both S- and AS-dimethylated and that PRMT5 and PRMT1 are competitors for Myc as a substrate. Furthermore, 
S-dimethylated Myc is the prevalent Myc species in GSCs grown as neurospheres whereas in differentiating 
GSCs its levels strongly decrease in a time-dependent manner. Differently, PRMT1 protein level and activity were 
weakly reduced during GSCs differentiation.
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Figure 3. PRMT1 and PRMT5 control Myc protein stability. FlagMyc/HEK293T cells (a) and GSCs (c) were 
treated with either DMSO, EPZ015666 or 9i for 24 hrs. Thereafter, cycloheximide was added along a time course 
between 0 and 100 minutes and western blot analysis was performed. FlagMyc/HEK293T cells (b) and GSCs (d) 
were treated with either EPZ01566 or 9i for 24 hrs. Thereafter, MG132 was added along a time course between 0 
and 360 minutes and western blot analysis was performed. *p < 0.05 vs DMSO. Uncropped images are shown in 
Supplementary Fig. S3a–d.
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PRMT1 and PRMT5 inhibition differentially modulates Myc recruitment at its target promoters 
in GSCs. To evaluate the effect of PRMT1 and PRMT5 on Myc binding at its specific chromatin loci in GSCs, 
ChIP experiments were performed, either in stem or differentiation conditions, in the presence or absence of 
EPZ015666 or 9i or control vehicle (Fig. 5). Two well known Myc promoter targets - cyclin D1 (CCND1) and the 
Epithelial Growth Factor Receptor variant III (EGFRvIII)37 - the stem gene promoters SRY-box 2 (SOX2), bound 
by Myc in GSCs34 together with the Glial Fibrillary Astrocytic Protein (GFAP) promoter38, were tested. In stem 
conditions, either PRMT5 or PRMT1 inhibition did not affect Myc binding on CCND1 and EGFRvIII promot-
ers. Conversely, SOX2 promoter was sensitive only to PRMT1 inhibition, whereas, either PRMT5 or PRMT1 
inhibition decreased Myc binding on GFAP promoter. Interestingly, Myc detached from all these promoters in 
differentiating control cells. PRMT5 inhibition had no effect on Myc recruitment in these experimental condi-
tions, whereas 9i treatment restored Myc binding above control levels only on CCND1 and EGRvIII promoters. 
Altogether, these data address a role to both PRMT5 and PRMT1 catalytic activity in regulating Myc loading at 
promoters.
PRMT5 affects GSCs cell cycle progression and neurospheres formation. To evaluate in depth the 
effect of either PRMT1 or PRMT5 on GSCs biological properties, cell cycle, neurospheres formation, viability and 
apoptosis were evaluated. Cell cycle analysis (Fig. 6a, left) shows that a low, but statistically significant, number 
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Figure 4. The ratio between Myc S-dimethylation and AS-dimethylation decreases upon cell differentiation. 
(a) GSCs were treated for 24 hrs with EPZ015666 (top) or 9i (bottom). Thereafter, immunoprecipitation 
experiments were performed by using either SYM10 or ASYM24 antibodies. Myc was revealed by an anti-Myc 
antibody. Inputs are shown on the right panels. Uncropped images are shown in Supplementary Fig. S4a.  
(b) Left. GSCs grown in 2% FBS containing medium along a time course between 4 hrs and 7 days. Thereafter, 
immunoprecipitation experiments were performed by using the SYM10 or the ASYM24 antibody, at each time 
point. Myc was revealed with an anti-Myc antibody. The densitometry, shown below the immunoprecipitation 
experiment, revealed a progressive reduction in S-Myc/AS-Myc ratio. Right panel. Immunoprecipitation 
experiment, showing the binding between Myc and PRMT1 at 7 days of FBS culture. PRMT5 was barely 
detectable. Input of both previous immunoprecipitation experiments is shown in the middle panel. Uncropped 
images are shown in Supplementary Fig. S4b. (c) The cartoon shows a model according to which S-Myc/AS-
Myc ratio decreases upon GSCs differentiation, consistent with the reduced levels of PRMT5. Abbreviations: 
SYM = SYM10; ASYM = ASYM24; OD = optical density.
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of GSCs treated for 7 days with EPZ015666 were arrested in S-phase, whereas an accumulation of cells in the 
subG1 phase was mostly observed upon 9i administration. Consistent with the role of PRMT5 in sustaining GSCs 
self-renewal28, neurospheres formation was extremely compromised after 10 days of EPZ015666 treatment, while 
9i had no effect, when compared to control solvent (Fig. 6a, middle). This was paralleled by a decrease of SOX2 
protein upon EPZ015666 exposure (Fig. 6a, right). Nevertheless, no differences in cell viability nor in apoptosis 
rate were observed in the presence of the two drugs, when compared to controls (not shown).
PRMT1 affects GSCs differentiation. As known, mesenchymal GSCs differentiate into astrocytes when 
cultured in the presence of foetal bovine serum (FBS)36 and we found that, in this condition, Myc is preferen-
tially AS-dimethylated (Fig. 4b). Therefore we asked whether the inhibition of either PRMT1 or PRMT5 cata-
lytic activity could modulate GSCs differentiation properties. To this aim, GSCs were pre-treated for 24 hrs with 
either EPZ015666 or 9i (or control vehicle); thereafter cells were shifted to FBS-containing medium and allowed 
to differentiate for 7 days. Drugs were refreshed every 48 hrs. Immunofluorescence analysis showed that con-
trol cells expressed GFAP but were negative for the stemness markers SOX2, Oct4, Nanog and Olig239 (Fig. 7a). 
Also TuJI, a neuronal marker, was undetectable, as expected. Comparable data were obtained with EPZ015666 
(Fig. 7b,d), whereas different results were observed upon PRMT1 inhibition. Differentiating GSCs exposed to 9i 
still did not express Olig2, TuJI, SOX2, Oct4 and Nanog proteins, and dramatically lost GFAP (Fig. 7c,d), as also 
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confirmed by a decrease in its mRNA level, as shown in panel e. mRNAs encoding for the other protein markers 
analyzed were not modulated, upon neither PRMT5 nor PRMT1 inhibition (not shown). Furthermore, since 
PRMT1 activity is associated with astrocytic differentiation40, we monitored H4R3me2as and H4R3me2s levels. 
A prevalence of H4R3me2as was observed in control and EPZ015666 treated cells. Consistently, 9i blocked H4R3 
AS-dimethylation, whereas a slight increase in H4R3me2s was observed (Fig. 7d). In summary, PRMT1 appears 
to support GSCs astrocytic differentiation, since its inhibition led to the loss of FBS-induced GFAP-positive cells. 
On the contrary, PRMT5 inhibition did not have any impact on GSCs commitment into the astrocytic lineage.
Discussion
GBM still represents a great challenge for oncologists. Its high genetic, epigenetic and phenotypic heterogeneity 
have made impossible to identify valuable therapeutic routes, so far. PRMT1, PRMT5 and Myc have been all 
indicated as important players in GBM progression5,41. Specifically, Myc and PRMT5 have been proved as master 
regulators of GSC pluripotency8,28, while PRMT1 loss does not affect typical pluripotency markers42. Myc inter-
acts with PRMT533 and PRMT1 is required for p300 recruitment at Myc-regulated gene promoters32. Further, 
PRMT1 and PRMT5 interact in GBM29. However, no direct association between Myc, PRMT1 and PRMT5 has 
been reported. Here we show, for the first time, that Myc, PRMT5 and PRMT1 form a ternary complex, both 
in recipient HEK293T cells and GSCs (Fig. 1c,d). More importantly, we show that Myc is dimethylated by both 
Figure 7. PRMT1 inhibition impairs GSCs astrocytic differentiation. (a–d) GSCs were pre-conditioned for 
24 hrs in the presence of EPZ015666, 9i or control vehicle. The day after, cells were dissociated and plated 
in DMEM/F12 plus 2% FBS for 7 days. Drugs were refreshed every 48 hrs. Thereafter, cells were fixed and 
processed in immunofluorescence analyses. (e) Real time PCR for GFAP. *p < 0.05 vs DMSO.
1 0Scientific RepoRtS |         (2019) 9:15925  | https://doi.org/10.1038/s41598-019-52291-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
PRMT1 and PRMT5 (Figs 2 and 4), being the presence of PRMT5 required for Myc/PRMT1 binding, at least 
in HEK293T cells (Figs 1f and 2e). Therefore, PRMT5 seems to function not only as a catalytic enzyme but 
also as a fundamental platform of the complex (Fig. 1f), at least in this cell system. Indeed, PRMT5 inhibition 
impaired also Myc AS-dimethylation (Fig. 2e). The inhibition of the catalytic activity of either PRMT1 or PRMT5 
enhances Myc S- or AS-dimethylation, respectively (Figs 2b,c and 4a), without disrupting the complex and indi-
cating that, as occurs for H4R3, they compete for Myc as a substrate. Myc dimethylation is consistent with the 
S- and AS-dimethylation of other transcription factors. Indeed, PRMT5 dimethylates and activates the Nuclear 
Factor kB (NF-kB) p65 subunit43, while AS-dimethylation by PRMT1 results in an impairment of the NF-kB RelA 
subunit binding to DNA44. Similarly, E2F-1 transcriptional specificity is regulated by either PRMT5-dependent 
S- or PRMT1-dependent AS-dimethylation, which are specifically induced by appropriate stimuli45. Further, 
NMyc, the neural-specific member of the Myc protein family, is both S- and AS-dimethylated by PRMT530 and 
PRMT131, respectively, and these modifications modulate protein stability. In this regard, our data show that, in 
both HEK293T cells and GSCs, PRMT5 stabilizes Myc (Fig. 3a,c, middle), while PRMT1 seems to regulate its 
proper turnover, as preventing PRMT1 catalytic activity maintained Myc protein levels constant upon de novo 
protein synthesis inhibition (Fig. 3a,c right) and induces a dramatic increase in GSCs Myc protein content, upon 
proteasome blockade (Fig. 3d, right). These results, together with the observation that GSCs possess an almost 
exclusively S-Myc when cultured in stem conditions (Fig. 4a), lead to the hypothesis that S-dimethylation may 
sustain Myc oncogenic function in GSCs. This is consistent with Myc and PRMT5 overexpression in GBM and 
with their role in supporting GSC stemness4,28. Inhibiting either PRMT1 or PRMT5 activity affects Myc recruit-
ment at some of its target promoters (Fig. 5). In stem conditions, we observed that Myc recruitment was either 
unaffected (CCND1 and EGFRvIII promoters) or sensitive to PRMT1 inhibition (SOX2 promoter) or to both 
PRMT1 and PRMT5 inhibition (GFAP promoter), indicating that Myc binding activity is modulated by PRMT1 
and PRMT5, either alone or in combination, in a gene-specific manner. Whether this phenomenon depends on 
Myc differential dimethylation, which may regulate its association to co-activators/co-repressors32, its promoter 
affinity and transcriptional specificity45 or on chromatin accessibility, which may impact Myc promoter binding 
efficacy, or on additive effects, is an issue still to be determined. Interestingly, upon differentiation Myc binding 
at promoters was strongly reduced and PRMT5 inhibition had a little impact on its recruitment, whereas PRMT1 
inhibition rescued Myc binding at CCND1 and EGFRvIII promoters above control levels. Since S-Myc strongly 
decreases upon 7 days of differentiation (Fig. 4b), it may be supposed that AS-Myc may have a lower affinity for 
chromatin, as occurs for RelA44, and inhibiting AS-dimethylation may partially restore Myc binding capacity, at 
least on a subset of promoters.
At the functional level, inhibiting PRMT5 catalytic activity led to a statistically significant S-phase cell cycle 
accumulation of a small GSCs population and to the failure of neurospheres generation, as also reported by 
others28 (Fig. 6). On the other hand, PRMT1, which has no impact on GSCs maintenance, seems to dramatically 
affect GSCs differentiation (Fig. 7). Indeed, arginine methylation is critical for the onset of neural specific lineages 
during embryogenensis. In particular, PRMT1 activity is important for astrocytic differentiation of embryonic 
neural precursors40. Consistently, we have found that PRMT1 catalytic inhibition impairs GSCs differentiation 
into astrocytes (Fig. 7), while the loss of PRMT5 activity did not affect GSCs differentiation properties. Along the 
GSCs differentiation process, we observed a progressive decrease of S-Myc, which was paralleled by a decrease in 
PRMT5 and Myc protein levels, whereas AS-Myc remained stable (Fig. 4b). Therefore, upon differentiation, the 
S-Myc/AS-Myc ratio changes, in favour of AS-Myc. Consistently, we still detected Myc/PRMT1 binding after 7 
days of differentiation (Fig. 4b, right), together with a residual amount of PRMT5 (Fig. 4b, middle). However, it 
has to be still determined whether Myc/PRMT1 interaction is direct or indirect and we cannot exclude the pres-
ence of other interactors to mediate Myc/PRMT1 association (see model in Fig. 4c).
We are aware that our observations lack mechanistic insights. In fact, the modifications in Myc binding ability 
at promoters (Fig. 5), GSCs cell cycle profile, failure of neurospheres formation (Fig. 6) and changes in the dif-
ferentiation capability (Fig. 7) cannot be definitely addressed to S- or AS-Myc species. The identification of Myc 
dimethylated arginine(s), the production of specific, either unmethylatable or methyl-mimicking, Myc mutants, 
followed by depletion/reconstitution experiments to substitute the endogenous wild type Myc, is still missing and 
will be object of our future investigations.
In conclusion, our work reports, for the first time, that Myc associates with both PRMT1 and PRMT5 being 
differentially dimethylated. S-dimethylation protects Myc from degradation, while AS-dimethylation allows 
Myc proper turnover. We hypothesize S-Myc as typical of aggressive GSCs, as S-Myc/AS-Myc ratio decreases in 
differentiating, less aggressive, cells (Fig. 4b). In this view, S-Myc species may be suggested as a novel diagnos-
tic and prognostic tool for GBM, once a specific antibody will be produced. Although thorough investigations 
are required to validate the hypothesis that S- or AS-Myc dimethylation may control Myc promoter specificity 
and/or binding (Fig. 5), this opens a completely new scenario on Myc epigenetic functions and may shed light 
onto some Myc properties which are not fully elucidated. Moreover, these findings suggest that acting on Myc 
S-dimethylation may represent a novel and unexplored therapeutic strategy for GBM, avoiding Myc complete 
silencing, which produces highly detrimental side effects in healthy cells.
Methods
Cell culture and treatments. HEK293T and mesenchymal Brain Tumour 168 Neural Stem Cells33,36 
were cultured as described33. For differentiation experiments, GSCs were cultured in Dulbecco’s Modified Eagle 
Medium/F12 mixture (1:1), 1% Glutamine, 1% Penicillin/Streptomycin and 2% Foetal Bovine Serum (FBS, 
Merck, Darmstadt, Germany).
EPZ015666 (Merck) was administered at a concentration of 5 μM and the PRMT1 inhibitor 1,5‐bis(3,5‐
Br2‐4‐hydroxyphenyl)‐1,4‐pentadien‐3‐one (9i) at 3 μM35. Control solvent was represented by dimethylsulfoxide 
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(DMSO, Merck). For GSCs differentiation and neurospheres formation experiments, drugs were refreshed every 
48 hrs. Cyclohexymide and MG132 (Merck) were 10 μg/ml and 10 μM, respectively.
Western blot analyses. Cells were directly lysed in Laemmli buffer and western blots were performed as 
described33. Anti-H4R3me2s (cat. #ab5823; dilution 1:1000), anti-H4R3me2as (cat. #ab194683; dilution 1:1000), 
anti-PRMT5 (cat. #ab109451; dilution 1:1000) and anti-PRMT1 (cat. #ab3768; dilution 1:400) antibodies 
were from Abcam (Cambridge, UK). Anti-Myc (clone 9E10, cat. #sc-40; dilution 1:500) was from Santa Cruz 
Biotechnology (Dallas, TX, U.S.A). Anti-actinHRP (cat. #A3854; dilution 1:5000) was from Merck. Anti-SOX2 
(cat. #MAB4343; dilution 1:500), SYM10 (cat. #07-412; dilution 1:1000) and ASYM24 (cat. #07-414; dilution 
1:1000) antibodies were from Millipore (Burlington, MA, U.S.A.). Anti-Flag antibody (cat. #F1804; dilution 
1:1000) was from Merck. Secondary anti-rabbit IgG (cat. #A0545; dilution 1:5000) and anti-mouse IgG (cat. 
#A9044; dilution 1:2000) were from Merck. In most cases, filters were directly cut after the blocking procedure, 
according to the molecular weight of the proteins of interest. Equipment and settings: images were captured with 
a ChemiDoc XRS+ Gel Imaging System (Bio-Rad, Hercules, CA, U.S.A) and the band intensity of western blot 
analysis was quantified using ImageJ software. When useful, contrast/brightness of western blot images were 
slightly adjusted with the Power Point software.
Immunoprecipitation. For immunoprecipitation experiments, cells were lysed in 140 mM NaCl, 10 mM 
Tris pH 7.6, 1% Triton X-100, 0.1% sodium deoxycholate, 1 mM EDTA, protease and phosphatase inhibitors. 
Cells were incubated on ice for 30′, then centrifuged for 20′ at 4 °C, at 13000 rpm. Thereafter, supernatant 
(1–2 mg) underwent immunoprecipitation as described33, by using 4 μg of each antibody or control IgGs (mouse 
IgGs were from Santa Cruz, cat. #sc-2025; rabbit IgGs were from Merck, #cat. I8140). To avoid IgGs detection, 
either ImmunoCruz IP/WB Optima B, C, F, E (Santa Cruz Biotechnology; cat. #sc-45039, cat. #sc-45040, cat. #sc-
45043, cat. #sc-45042, respectively) or the VeriBlot reagent (Abcam; #cat. ab131366 and #ab131368) were used in 
western blot, after the immunoprecipitation procedure, according to the manufacturer’s instructions.
Plasmid transfection and lentiviral transduction. Plasmid transfections were performed by 
using Lipofectamine 2000 (ThermoFisher Scientific, Waltham, MA, U.S.A.) according to the manufactur-
er’s instructions. Plasmids were: pCBSFlagMyc33, pCMVPRMT5-6myc (courtesy of dr. Levi A.) and pCM-
V6PRMT1-myc-Dkk (Origene, Rockville, MD, U.S.A), together with the corresponding empty vectors. The 
shMyc insert was subcloned from the KRAB lentiviral vector into the Tet-on pSLIK lentivirus33. Lentiviral pro-
duction and infection were performed as described33.
siRNA transfection. siPRMT5, siPRMT1 (ON-Target Plus Human PRMT5 and PRMT1 siRNA, 
Dharmacon, Lafayette, CO, U.S.A.) and scrambled siRNAs (#sc-44230, Santa Cruz Biotechnology) were trans-
fected by using the DHARMAFect reagent (Dharmacon), according to the manufacturer’s instructions.
In vitro methylation assay. For in vitro methylation assays, HEK293T cells (3,5 × 106) were transfected 
with 50 nM siRNAs (or scrambled siRNA) and the day after with either PRMT5-6myc or PRMT1-myc-Dkk plas-
mids or control vectors (10 μg). 48 hrs later, cells were lysed in 20 mM Hepes pH 7.9, 137 mM NaCl, 20% Glycerol, 
1% Nonidet P40, 2 mM EDTA, protease and phosphatase inhibitors. Cell extracts were kept in rotation for 30′, 
at 4 °C and then centrifuged at 12000 rpm for 20′ at 4 °C. Cell extracts were pre-cleared with 5 μg of control IgGs, 
for 1 hr, on ice; thereafter, 20 μl of equilibrated protein A/G Plus agarose beads (Santa Cruz Biotechnology; cat. 
#sc-2003) were added and the mixture was kept in rotation for 30′, at +4 °C. and then centrifuged at 10000 rpm, 
at 4 °C. The supernatant was incubated with either anti-Myc antibody (Santa Cruz Biotechnology), or control 
IgG, for an overnight, at 4 °C (to purify either overexpressed PRMT5-6myc or PRMT1-myc-Dkk). The day after, 
40 μl of equilibrated protein A/G Plus agarose beads were added and the mixture was incubated in rotation for 4 
hrs, at 4 °C. Beads were extensively washed with lysis buffer by centrifuging at 3000 rpm, at 4 °C. Beads and bound 
PRMT5-6myc or PRMT1-myc-Dkk were resuspended in assay buffer (20 mM Tris HCl pH 7.5, 20% glycerol, 
100 mM KCl, 1 mM DTT, 0.2 mM EDTA, protease and phosphatase inhibitors) and 500 ng of human recombinant 
c-Myc protein (Abcam; cat. #ab84132) plus 1 mM of S-adenosylmethionine (Merck) were added. The reaction 
mixture (100 μl) was incubated for 1 hr, at 35 °C. Thereafter, 400 μl of assay buffer were added, and dimethylated 
Myc was immunoprecipitated by incubating the reaction mixture with 4 μg of either SYM10 or ASYM24 antibody 
(Millipore), for an overnight, at 4 °C. The day after, 40 μl of equilibrated protein A/G Plus agarose beads were 
added and the mixture incubated for 4 hrs, in rotation, at 4 °C. After three washes in assay buffer, 20 μl of Laemmli 
buffer 2X were added and the immunocomplexes boiled for 5′. Dimethylated Myc was revealed by western blot.
Immunofluorescence analyses. Immunofluorescence analyses were performed as described33. Anti-Olig2 
(cat. #sc-293163; dilution 1:50), anti- TuJI (cat. #sc-51670; dilution 1:50), anti-Oct4 (cat. #sc-101534; dilution 
1:50) antibodies were from Santa Cruz Biotechnology; anti-SOX2 (cat. #MAB4343; dilution 1:50) and anti-Nanog 
(clone 7F7.1, cat. #MABD24; dilution 1:50) were from Millipore. Anti-GFAP (cat. #ab7260; dilution 1:100), 
anti-H4R3me2s (cat. #ab5823; dilution 1:100) and anti-H4R3me2as (cat. #ab194683; dilution 1:100) were from 
Abcam. Secondary antibodies were donkey anti-rabbit IgG Alexa Fluor 555 (cat. #A-31572; dilution 1:100) and 
goat anti-mouse Alexa Fluor 488 (cat.# A-11029; dilution 1:100), both from Thermo Fisher Scientific.
Cell cycle analysis. Cells were dissociated, counted, resuspended in PBS and then fixed in 70% ethanol for a 
minimum of 24 hrs. After three washes in PBS, cells were incubated with 50 μg/ml Propidium Iodide (Merck) plus 
0.1 U/L RNAse (Merck) for 3 hrs at room temperature before FACS analysis by Coulter Epics XL flow cytometer 
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(Beckman Coulter, Brea, CA, U.S.A.). Cells were gated using both area vs peak to eliminate doublets and forward 
vs side scatter to exclude debris. The percentage of cells in the different cycle phases and in subG1 (composed of 
dead cells and debris) was calculated using FACS Express5 Flow Research Edition software.
Neurospheres formation. 3 × 105 GSCs were plated in duplicate into a six-well multi-plate. Cells were 
allowed to grow for 10 days, in the presence or absence of EPZ015666 or 9i or control vehicle. Neurospheres 
formation was monitored daily by a phase contrast microscope. Images were captured with the ZOE Fluorescent 
Cell Imager (Bio-Rad).
Real time PCR. Real time PCR were performed as described33.
Chromatin Immunoprecipitation. Chromatin immunoprecipitations were performed as described46.
Oligonucleotides. ChIPs oligonucleotides were:
hEGFRv3prom_F GGCTGTTTGTGTCAAGCCTTTA
hEGFRv3prom_R TTGAAGCCAATGTGTGAAGCA
hSOX2prom_F AACGGACGTGCTGCCATT
hSOX2prom_R TCCCATTGTCCCGACGTAAA
hGFAPprom_F TGGGAATGAGGCCTAGTAGGAA
hGFAPprom_R GGGAATTTGGCGAAGAATGA
hCCND1prom_F GCTTTCCATTCAGAGGTGTGTTT
hCCND1prom_R CTACCTTGACCAGTCGGTCCTT
GFAP oligonucleotides used in real time PCR experiments were:
GFAP_F ACCAGGACCTGCTCAATGTC
GFAP_R ATCTCCACGGTCTTCACCAC
Quantification and statistical analyses. All data are expressed as mean ± SEM, and significance 
(p value) was calculated using two-tailed paired Student’s t test; p values < 0.05 were considered statistically 
significant.
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